Best Stocks Under $5 Right Now

Show:
Clean Energy Fuels stock logo

#1 - Clean Energy Fuels

NASDAQ:CLNE
Stock Price:
$2.59 (-$0.03)
P/E Ratio:
-7.40
Market Cap:
$578.24 million
Average Trading Volume:
1.59 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$5.60 (116.2% Upside)
Clean Energy Fuels Corp. provides natural gas as alternative fuels for vehicle fleets and related fueling solutions in the United States and Canada. It supplies renewable natural gas (RNG), compressed natural gas (CNG), and liquefied natural gas (LNG) for medium and heavy-duty vehicles; and offers operation and maintenance services for public and private vehicle fleet customer stations. The company also designs, builds, operates, and maintains vehicle fueling stations; and sells and services compressors and other equipment that are used in RNG production and fueling stations. In addition, it transports and sells CNG, RNG, and LNG through virtual natural gas pipelines and interconnects; sells U.S. federal, state, and local government credits, such as RNG as a vehicle fuel, including Renewable Identification Numbers and Low Carbon Fuel Standards credits; and obtains federal, state, and local credits, grants, and incentives. Further, the company focuses on developing, owning, and operating dairy and other livestock waste RNG projects. It serves heavy-duty trucking, airports, refuse, public transit, industrial, and institutional energy users, as well as government fleets. Clean Energy Fuels Corp. was incorporated in 2001 and is headquartered in Newport Beach, California.
Ocuphire Pharma stock logo

#2 - Ocuphire Pharma

NASDAQ:OCUP
Stock Price:
$1.69 (-$0.05)
P/E Ratio:
-3.44
Market Cap:
$43.68 million
Average Trading Volume:
195,803 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$18.75 (1,012.8% Upside)
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.
PMV Pharmaceuticals stock logo

#3 - PMV Pharmaceuticals

NASDAQ:PMVP
Stock Price:
$2.10 (-$0.05)
P/E Ratio:
-1.58
Market Cap:
$108.02 million
Average Trading Volume:
527,929 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$5.75 (173.8% Upside)
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
Aquestive Therapeutics stock logo

#4 - Aquestive Therapeutics

NASDAQ:AQST
Stock Price:
$3.11 (-$0.17)
P/E Ratio:
-7.40
Market Cap:
$283.13 million
Average Trading Volume:
2.19 million shares
Consensus Rating:
Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$8.00 (157.2% Upside)
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
DocGo stock logo

#5 - DocGo

NASDAQ:DCGO
Stock Price:
$3.08 (-$0.12)
P/E Ratio:
15.40
Market Cap:
$312.84 million
Average Trading Volume:
1.03 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$7.75 (151.6% Upside)
DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.
Taysha Gene Therapies stock logo

#6 - Taysha Gene Therapies

NASDAQ:TSHA
Stock Price:
$3.09 (-$0.05)
P/E Ratio:
-6.31
Market Cap:
$577.89 million
Average Trading Volume:
1.57 million shares
Consensus Rating:
Buy (9 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$7.00 (126.5% Upside)
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Flux Power stock logo

#7 - Flux Power

NASDAQ:FLUX
Stock Price:
$3.21 (-$0.12)
P/E Ratio:
-7.47
Market Cap:
$53.54 million
Average Trading Volume:
89,462 shares
Consensus Rating:
Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$9.50 (196.0% Upside)
Flux Power Holdings, Inc., through its subsidiary Flux Power, Inc., designs, develops, manufactures, and sells lithium-ion energy storage solutions for lift trucks, airport ground support equipment, and other industrial and commercial applications in the North America. It offers battery management system (BMS) that provides cell balancing, charging, discharging, monitoring, and communication between the pack and the forklift. The company also provides 24-volt onboard chargers for its Class 3 Walkie pallet packs; and smart wall mounted chargers to interface with its BMS. It sells its products directly to small companies and end-users, as well as through original equipment manufacturers, lift equipment dealers, and battery distributors. The company is headquartered in Vista, California.
Rezolute stock logo

#8 - Rezolute

NASDAQ:RZLT
Stock Price:
$2.64 (+$0.08)
P/E Ratio:
-2.32
Market Cap:
$105.94 million
Average Trading Volume:
268,366 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$8.80 (233.3% Upside)
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
TeraWulf stock logo

#9 - TeraWulf

NASDAQ:WULF
Stock Price:
$1.95 (-$0.07)
Market Cap:
$649.70 million
Average Trading Volume:
13.44 million shares
Consensus Rating:
Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$3.66 (87.6% Upside)
TeraWulf Inc., together with its subsidiaries, operates as a digital asset technology company in the United States. The company develops, owns, and operates bitcoin mining facilities in New York and Pennsylvania. It is also involved in the provision of miner hosting services to third-party entities. The company was founded in 2021 and is headquartered in Easton, Maryland.
Bitfarms stock logo

#10 - Bitfarms

NASDAQ:BITF
Stock Price:
$1.75 (-$0.01)
P/E Ratio:
-4.61
Market Cap:
$685.65 million
Average Trading Volume:
15.29 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$4.00 (128.6% Upside)
Bitfarms Ltd. engages in the mining of cryptocurrency coins and tokens in Canada, the United States, Paraguay, and Argentina. It owns and operates server farms that primarily validates transactions on the Bitcoin Blockchain and earning cryptocurrency from block rewards and transaction fees. The company also provides electrician services to commercial and residential customers in Quebec, Canada. It also undertakes hosting of third-party mining hardware. The company was founded in 2017 and is based in Toronto, Canada.
Checkpoint Therapeutics stock logo

#11 - Checkpoint Therapeutics

NASDAQ:CKPT
Stock Price:
$1.88 (+$0.10)
P/E Ratio:
-0.68
Market Cap:
$67.10 million
Average Trading Volume:
401,506 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$22.60 (1,102.1% Upside)
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is also developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Biodesix stock logo

#12 - Biodesix

NASDAQ:BDSX
Stock Price:
$1.58 (+$0.01)
P/E Ratio:
-2.86
Market Cap:
$180.64 million
Average Trading Volume:
86,532 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$3.10 (96.8% Upside)
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Unicycive Therapeutics stock logo

#13 - Unicycive Therapeutics

NASDAQ:UNCY
Stock Price:
$1.04 (+$0.01)
P/E Ratio:
-0.87
Market Cap:
$39.11 million
Average Trading Volume:
341,270 shares
Consensus Rating:
Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$5.30 (409.6% Upside)
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Dragonfly Energy stock logo

#14 - Dragonfly Energy

NASDAQ:DFLI
Stock Price:
$1.12 (+$0.11)
P/E Ratio:
-2.07
Market Cap:
$67.77 million
Average Trading Volume:
1.14 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$1.80 (60.7% Upside)
Dragonfly Energy Holdings Corp. engages in the manufacturing and sale of deep cycle lithium-ion batteries for recreational vehicles, marine vessels, solar and off-grid residence industries, and industrial and energy storage markets. The company provides lithium power systems comprising solar panels, chargers and inverters, system monitoring, alternator regulators, accessories, and others. It also offers battery management systems for monitoring and controlling of battery systems and to protect battery cells from damage in various scenarios. The company provides its products under the Dragonfly Energy, Battle Born, and Wakespeed brand names. Dragonfly Energy Holdings Corp. is headquartered in Reno, Nevada.
Aptose Biosciences stock logo

#15 - Aptose Biosciences

NASDAQ:APTO
Stock Price:
$1.18 (-$0.01)
P/E Ratio:
-0.19
Market Cap:
$19.22 million
Average Trading Volume:
50,632 shares
Consensus Rating:
Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$17.50 (1,383.1% Upside)
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Carisma Therapeutics stock logo

#16 - Carisma Therapeutics

NASDAQ:CARM
Stock Price:
$1.41 (+$0.04)
P/E Ratio:
-0.71
Market Cap:
$58.57 million
Average Trading Volume:
147,461 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$8.60 (509.9% Upside)
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Redwire stock logo

#17 - Redwire

NYSE:RDW
Stock Price:
$4.86 (-$0.01)
P/E Ratio:
-6.75
Market Cap:
$318.72 million
Average Trading Volume:
197,616 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$6.75 (38.9% Upside)
Redwire Corporation provides critical space solutions and space infrastructure for government and commercial customers in the United States, Europe, and internationally. The company provides avionics and sensors including star trackers, sun sensors, critical for navigation, and control of spacecraft; camera systems; solar array solutions for spacecraft spanning the spectrum of size, power needs, and orbital location; and strain composite booms, coilable booms, truss structures, telescope baffles, and deployable booms to position sensors or solar arrays away from the spacecraft. It offers software suite that enables digital engineering and generation of high-fidelity, interactive modeling and simulations of individual components, entire spacecraft, and full constellations in a cloud-based environment. In addition, the company microgravity payloads, radio frequency systems, antennas, star trackers, platforms, and in-space manufacturing and biotech facilities. Redwire Corporation is headquartered in Jacksonville, Florida.
Perspective Therapeutics stock logo

#18 - Perspective Therapeutics

NYSEAMERICAN:CATX
Stock Price:
1.60 (+0.07)
Market Cap:
$952.62 million
Average Trading Volume:
5.98 million shares
Consensus Rating:
Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.
Savara stock logo

#19 - Savara

NASDAQ:SVRA
Stock Price:
$4.48 (-$0.24)
P/E Ratio:
-12.11
Market Cap:
$619.09 million
Average Trading Volume:
902,356 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$8.80 (96.4% Upside)
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Applied Digital stock logo

#20 - Applied Digital

NASDAQ:APLD
Stock Price:
$4.14 (+$0.48)
P/E Ratio:
-5.24
Market Cap:
$508.52 million
Average Trading Volume:
3.38 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$9.60 (131.9% Upside)
Applied Digital Corporation designs, develops, and operates datacenters in North America. Its datacenters provide digital infrastructure solutions to the high-performance computing industry. The company also provides artificial intelligence cloud services, high performance computing datacenter hosting, and crypto datacenter hosting services. The company was formerly known as Applied Blockchain, Inc. and changed its name to Applied Digital Corporation in November 2022. Applied Digital Corporation is based in Dallas, Texas.
Pyxis Oncology stock logo

#21 - Pyxis Oncology

NASDAQ:PYXS
Stock Price:
$4.15 (-$0.02)
P/E Ratio:
-3.05
Market Cap:
$244.39 million
Average Trading Volume:
410,889 shares
Consensus Rating:
Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$8.80 (112.0% Upside)
Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Applied Therapeutics stock logo

#22 - Applied Therapeutics

NASDAQ:APLT
Stock Price:
$4.19 (-$0.06)
P/E Ratio:
-2.28
Market Cap:
$478.79 million
Average Trading Volume:
738,403 shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$11.00 (162.5% Upside)
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Taboola.com stock logo

#23 - Taboola.com

NASDAQ:TBLA
Stock Price:
$4.32 (-$0.02)
P/E Ratio:
-18.78
Market Cap:
$1.26 billion
Average Trading Volume:
1.05 million shares
Consensus Rating:
Buy (5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$5.79 (34.0% Upside)
Taboola.com Ltd., together with its subsidiaries, operates an artificial intelligence-based algorithmic engine platform in Israel, the United States, the United Kingdom, Germany, and internationally. It offers Taboola, a platform that partners with websites, devices, and mobile apps to recommend editorial content and advertisements on the open web to users. The company was incorporated in 2006 and is headquartered in New York, New York.
Annexon stock logo

#24 - Annexon

NASDAQ:ANNX
Stock Price:
$4.33 (-$0.03)
P/E Ratio:
-2.95
Market Cap:
$400.14 million
Average Trading Volume:
1.87 million shares
Consensus Rating:
Buy (6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$14.14 (226.6% Upside)
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Sagimet Biosciences stock logo

#25 - Sagimet Biosciences

NASDAQ:SGMT
Stock Price:
$4.62 (-$0.13)
Market Cap:
$147.42 million
Average Trading Volume:
423,149 shares
Consensus Rating:
Buy (7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$38.80 (739.8% Upside)
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Ideas from MarketBeat